The nation of Zimbabwe has rejected a significant American health deal worth 367 million US dollars (£272m) spanning five years due to the United States' insistence on sensitive data.
This rejection was revealed following a internal memorandum from December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "skewed".
An official representative later clarified that the US was demanding access to biological samples for research and commercial gain while refused to share the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of winding down our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for more talks to reach a agreement suitable to both sides so the country's critical HIV treatment initiative can be sustained.
Broader Context
This development follows a similar situation in Kenya, where a high court blocked a similar health funding agreement after concerns were filed about the security of citizens' medical information.
Since resuming office recently, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed assistance for the American government, but Trump stated its spending was "wasteful" and his administration was pursuing government-to-government deals to enhance openness and accountability.
According to statements, Sixteen African countries have so far signed these new agreements, representing over $18.3bn in new funding.
Details of the Declined Agreement
The funds for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment via American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data indefinitely, without any equivalent promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," his statement read.
"Effectively, our country would provide the raw materials for scientific discovery without any assurance that the final treatments would be available to our citizens should a new health crisis emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were upending frameworks already established via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with potential global health emergencies.
"This mechanism is designed to ensure that when a country provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome further discussions with our US partners on how future co-operation might be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the government's concerns, but recommended that talks must proceed since a large portion of the nation's HIV programmes relied on external financing.
"Where specific concerns exist, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," it added.
The halted deal emphasises the complex tensions between receiving much-needed foreign assistance and safeguarding local interests in an ever more data-driven world.